Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivoglitazone monotherapy versus placebo and pioglitazone in type 2 diabetes mellitus
2006-005047-28Phase 3Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rivoglitazone in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in HbA1c from baseline to Week 26. Started Dec 2006; status: terminated.
02
Drugs
rivoglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-005047-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005047-28.